SUBSCRIBE: Print / eNewsletter
Nivolumab New Care Option for Head and Neck Cancer
Immunotherapy treatment with nivolumab significantly improved survival among patients with recurrent or metastatic head and neck squamous cell carcinoma.
Pembrolizumab Effective in Metastatic Head and Neck Cancer
Pembrolizumab demonstrated a 24.8% overall response rate in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
FDA Approves Lenvatinib for Thyroid Cancer
The FDA has approved lenvatinib (Lenvima) for the treatment of patients with progressive, differentiated thyroid cancer refractory to radioactive iodine.